DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pimodivir
Pimodivir
Microorganisms-07-00521-V2.Pdf
Current and Novel Approaches in Influenza Management
English (PDF)
Study Protocol
Study Protocol
To Download a Copy of Agencyiq's COVID-19 Development Tracker
Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018
Unconventional Viral Gene Expression Mechanisms As Therapeutic Targets
Current and Future Antiviral Medications to Treat Influenza: Mechanisms of Action
A Meeting Report from the 6Th Isirv Antiviral Group Conference T
Stembook 2018.Pdf
Epidemics of Infectious Diseases in Human History. Antiviral Drugs and Vaccines in the Development Stage to Protect Against Coronavirus SARS- Cov-2
Supplementary Information Table S1. Approved, Investigational
Review : Imunoterapi Penanganan Infeksi Virus
Repurposing of FDA Approved Drugs
“New Influenza Antivirals”
Repurposing of FDA Approved Drugs for the Identification of Potential Inhibitors of SARS-Cov-2 Main Protease
To Download the Latest COVID-19 Drug and Vaccine Development Tracker
Top View
The Business Case for Building the Janssen Brand
Product List
In Silico Molecular Dynamics Docking of Drugs to the Inhibitory Active Site of SARS-Cov-2 Protease and Their Predicted Toxicology and ADME
Programme Tuesday November 13
Identification of 3-Chymotrypsin Like Protease (3Clpro)
Synergistic Interferon Alpha-Based Drug Combinations Inhibit SARS
Comprehensive Profiling of Mutations to Influenza Virus PB2 That Confer Resistance to the Cap-Binding Inhibitor Pimodivir
Annexes to the 2019 Annual Report of the European Medicines Agency
J&J Plans 10 Potential Blockbuster Filings by 2023
Computationally Repurposed Drugs and Natural Products Against RNA Dependent RNA Polymerase As Potential COVID-19 Therapies
Bioactive Compound Library Plus (96-Well)
COVID-19: the Competitive Landscape for Medical Product Development
Drug Repurposing Compound Library Plus (96-Well)
Comprehensive Profiling of Mutations to Influenza Virus PB2 That
Influenza Virus and SARS-Cov-2: Pathogenesis and Host Responses in the Respiratory Tract
Emerging Antibiotics for Community-Acquired Pneumonia
Pathogenesis of Rna Virus and Recently
Influenza Virus
Remdesivir from Wikipedia, the Free Encyclopedia
D41586-019-02753-8.Pdf
Anti-Infection
Drug Repurposing Compound Library (96-Well)
Current Landscape and Future Prospects of Antiviral Drugs Derived from Microbial Products
Characterization of Influenza Virus Variants Induced by Treatment With
Influenza Virus Polymerase Inhibitors in Clinical Development
Synergistic Interferon Alpha-Based Drug Combinations Inhibit SARS-Cov-2 and Other Viral Infections in Vitro
Generic Pipeline Forecast This Section Provides a Summary of Upcoming First-Time Generic Drugs and Biosimilars That May Be Approved in the Upcoming Two Years